Reply to J. Richter et al.

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2823-2824

  Rousselot, Philippe ^a   Charbonnier, Aude ^b   Cony Makhoul, Pascale ^c   Agape, Philippe ^d   Nicolini, Franck E ^e   Varet, Bruno ^f   Gardembas, Martine ^g   Etienne, Gabriel ^h   Réa, Delphine ⁱ   Roy, Lydia ^j   Escoffre Barbe, Martine ^k   Guerci Bresler, Agnès ^l   Tulliez, Michel ^m   Prost, Stéphane ⁿ   Spentchian, Marc ^o   Cayuela, Jean Michel ⁱ   Reiffers, Josy ^p   Chomel, Jean Claude ^h   Turhan, Ali ^h   Guilhot, Joëlle ^j   Guilhot, François ^j   Mahon, François Xavier ^q   more..

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c Hopital d'Annecy   (France)

^d Hôpital Felix Guyon Centre Hôpital Universitaire CHU de la Réunion   (Reunion)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h INSTITUT BERGONIÉ   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j POITIERS UNIVERSITY HOSPITAL   (France)

^k PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^l CHU NANCY BRABOIS   (France)

^m HENRI MONDOR HOSPITAL   (France)

ⁿ CEA   (France)

^o CENTRE HOSPITALIER DE VERSAILLES   (France)

^p Université Poitiers et Paris Sud 11   (France)

^q HAUT LÉVÊQUE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; FEMALE; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84906822342     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.3858     Document Type: Letter

References (7)

1. Richter J, Söderlund S, Lübking A, et al: Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: A tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol 32:2821-2823, 2014
2. Rousselot P, Charbonnier A, Cony-Makhoul P, et al: Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424-430, 2014
3. Rousselot P, Huguet F, Rea D, et al: Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58-60, 2007
4. Mahon FX, Réa D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre, Stop IMatinib (STIM) trial. Lancet Oncol 11:1029-1035, 2010
5. Magro F, Costa C: Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. Inflamm Bowel Dis 12:1087-1089, 2006
6. Ceko M, Milenkovic N, Le Coutre P, et al: Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humans. Pain 155:1222-1228, 2014
7. Ramanujam D, McNicholl F, Furby D, et al: Dramatic resolution of respiratory symptoms with imatinib mesylate in patients with chronic myeloid leukemia presenting with lower airway symptoms resembling asthma. Leuk Lymphoma 50:1721-1722, 2009